CN102665768B - 肽清除剂 - Google Patents
肽清除剂 Download PDFInfo
- Publication number
- CN102665768B CN102665768B CN201080042526.6A CN201080042526A CN102665768B CN 102665768 B CN102665768 B CN 102665768B CN 201080042526 A CN201080042526 A CN 201080042526A CN 102665768 B CN102665768 B CN 102665768B
- Authority
- CN
- China
- Prior art keywords
- peptide
- enzyme
- scavenger
- binding
- cpg2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BNFWSLYKLRUAEY-LBPRGKRZSA-N Nc1c(C(N[C@@H](CCC(O)=O)C(O)=O)=O)c2ccccc2cc1 Chemical compound Nc1c(C(N[C@@H](CCC(O)=O)C(O)=O)=O)c2ccccc2cc1 BNFWSLYKLRUAEY-LBPRGKRZSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Nanotechnology (AREA)
- Genetics & Genomics (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0916749.5A GB0916749D0 (en) | 2009-09-23 | 2009-09-23 | Peptide cleaning agents |
| GB0916749.5 | 2009-09-23 | ||
| PCT/GB2010/001796 WO2011036457A1 (en) | 2009-09-23 | 2010-09-23 | Peptide clearing agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102665768A CN102665768A (zh) | 2012-09-12 |
| CN102665768B true CN102665768B (zh) | 2015-01-21 |
Family
ID=41327500
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080042526.6A Expired - Fee Related CN102665768B (zh) | 2009-09-23 | 2010-09-23 | 肽清除剂 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8846861B2 (enExample) |
| EP (1) | EP2470216A1 (enExample) |
| JP (1) | JP2013505287A (enExample) |
| KR (1) | KR20120084298A (enExample) |
| CN (1) | CN102665768B (enExample) |
| AU (1) | AU2010299643B2 (enExample) |
| BR (1) | BR112012006389A2 (enExample) |
| CA (1) | CA2774081A1 (enExample) |
| GB (1) | GB0916749D0 (enExample) |
| IL (1) | IL218713A0 (enExample) |
| IN (1) | IN2012DN02241A (enExample) |
| MX (1) | MX2012003565A (enExample) |
| NZ (1) | NZ598802A (enExample) |
| SG (1) | SG179015A1 (enExample) |
| WO (1) | WO2011036457A1 (enExample) |
| ZA (1) | ZA201201527B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2435510A (en) | 2006-02-23 | 2007-08-29 | Mologic Ltd | Enzyme detection product and methods |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| CN108117586A (zh) | 2010-08-10 | 2018-06-05 | 洛桑聚合联合学院 | 红细胞结合性治疗剂 |
| EA201691686A1 (ru) | 2014-02-21 | 2017-03-31 | Эколь Политекник Федераль Де Лозан (Эпфл) | Терапевтические средства с углевод-опосредованной адресной доставкой |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| EA202092723A1 (ru) | 2018-05-09 | 2021-04-09 | Зе Юниверсити Оф Чикаго | Композиции и способы, касающиеся иммунной толерантности |
| WO2021155317A1 (en) | 2020-01-31 | 2021-08-05 | Avilar Therapeutics, Inc. | Asgpr-binding compounds for the degradation of extracellular proteins |
| KR20240017423A (ko) | 2021-05-03 | 2024-02-07 | 아빌라 테라퓨틱스, 인크. | 이뮤노글로불린 및 다른 단백질의 분해를 위한 강력한 asgpr-결합 화합물 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997020580A1 (en) * | 1995-12-06 | 1997-06-12 | Aepact Limited | Drug therapy |
| WO1998024478A2 (en) * | 1996-11-30 | 1998-06-11 | Enzacta R & D Limited | Tumour therapy |
| US6172045B1 (en) * | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6075010A (en) | 1992-06-09 | 2000-06-13 | Neorx Corporation | Small molecular weight ligand-hexose containing clearing agents |
| US4859449A (en) | 1987-09-14 | 1989-08-22 | Center For Molecular Medicine And Immunology | Modified antibodies for enhanced hepatocyte clearance |
| US20030068322A1 (en) | 1988-04-18 | 2003-04-10 | Immunomedics, Inc. | Methods of antibody-directed enzyme-prodrug therapy |
| WO1991017761A1 (en) | 1990-05-11 | 1991-11-28 | The University Of Connecticut | Targeted protection from cytotoxins |
| GB9324807D0 (en) | 1993-12-03 | 1994-01-19 | Cancer Res Campaign Tech | Tumour antibody |
| ATE458499T1 (de) | 1995-06-07 | 2010-03-15 | Immunomedics Inc | Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort |
| WO1998019162A1 (en) * | 1996-10-31 | 1998-05-07 | Novalon Pharmaceutical Corporation | Identification of drugs using complementary combinatorial libraries |
| US6962702B2 (en) * | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| US7138103B2 (en) | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| US6465612B1 (en) * | 1998-09-23 | 2002-10-15 | The Regents Of The University Of California | Synthetic peptides, conjugation reagents and methods |
| JP2004535560A (ja) * | 2001-04-20 | 2004-11-25 | ザ ユニヴァーシティ オブ ジョージア リサーチファウンデーション， インク． | 活性部位不活性化因子 |
| WO2007038619A2 (en) * | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| ATE514711T1 (de) | 2007-10-16 | 2011-07-15 | Toscana Biomarkers S R L | Galactosylierte peptide, deren zubereitung und verwendung zur diagnose von autoimmunerkrankungen |
-
2009
- 2009-09-23 GB GBGB0916749.5A patent/GB0916749D0/en not_active Ceased
-
2010
- 2010-09-23 KR KR1020127010173A patent/KR20120084298A/ko not_active Withdrawn
- 2010-09-23 US US13/497,967 patent/US8846861B2/en not_active Expired - Fee Related
- 2010-09-23 WO PCT/GB2010/001796 patent/WO2011036457A1/en not_active Ceased
- 2010-09-23 EP EP10757623A patent/EP2470216A1/en not_active Withdrawn
- 2010-09-23 JP JP2012530331A patent/JP2013505287A/ja active Pending
- 2010-09-23 SG SG2012015806A patent/SG179015A1/en unknown
- 2010-09-23 IN IN2241DEN2012 patent/IN2012DN02241A/en unknown
- 2010-09-23 MX MX2012003565A patent/MX2012003565A/es not_active Application Discontinuation
- 2010-09-23 BR BR112012006389A patent/BR112012006389A2/pt not_active IP Right Cessation
- 2010-09-23 NZ NZ598802A patent/NZ598802A/xx not_active IP Right Cessation
- 2010-09-23 AU AU2010299643A patent/AU2010299643B2/en not_active Ceased
- 2010-09-23 CA CA2774081A patent/CA2774081A1/en not_active Abandoned
- 2010-09-23 CN CN201080042526.6A patent/CN102665768B/zh not_active Expired - Fee Related
-
2012
- 2012-02-29 ZA ZA2012/01527A patent/ZA201201527B/en unknown
- 2012-03-18 IL IL218713A patent/IL218713A0/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6172045B1 (en) * | 1994-12-07 | 2001-01-09 | Neorx Corporation | Cluster clearing agents |
| WO1997020580A1 (en) * | 1995-12-06 | 1997-06-12 | Aepact Limited | Drug therapy |
| WO1998024478A2 (en) * | 1996-11-30 | 1998-06-11 | Enzacta R & D Limited | Tumour therapy |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010299643A1 (en) | 2012-03-22 |
| IL218713A0 (en) | 2012-05-31 |
| MX2012003565A (es) | 2012-08-03 |
| WO2011036457A1 (en) | 2011-03-31 |
| JP2013505287A (ja) | 2013-02-14 |
| CN102665768A (zh) | 2012-09-12 |
| AU2010299643B2 (en) | 2014-06-26 |
| CA2774081A1 (en) | 2011-03-31 |
| IN2012DN02241A (enExample) | 2015-08-21 |
| US8846861B2 (en) | 2014-09-30 |
| NZ598802A (en) | 2013-10-25 |
| BR112012006389A2 (pt) | 2016-11-22 |
| ZA201201527B (en) | 2013-05-29 |
| US20130053543A1 (en) | 2013-02-28 |
| SG179015A1 (en) | 2012-04-27 |
| GB0916749D0 (en) | 2009-11-04 |
| KR20120084298A (ko) | 2012-07-27 |
| EP2470216A1 (en) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102665768B (zh) | 肽清除剂 | |
| JP7116217B2 (ja) | Ｍｔ１－ｍｍｐに特異的な二環性ペプチドリガンド | |
| JP7417432B2 (ja) | 新規リンカー、その製造方法およびその応用 | |
| US20230151068A1 (en) | Peptide compositions and methods of use thereof for disrupting tead interactions | |
| US12492224B2 (en) | Bicyclic peptide ligands specific for PD-L1 | |
| JP7291395B2 (ja) | ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾 | |
| KR101523705B1 (ko) | Ｓｐａｒｃ 결합 ｓｃｆｖｓ | |
| AU2010203353B2 (en) | Modified antibody compositions, methods of making and using thereof | |
| ES2855998T3 (es) | Etiqueta transglutamina para bioconjugación específica de sitio eficiente | |
| JP5677454B2 (ja) | 細胞内ターゲット結合用二座ペプチドバインダー | |
| JP5677453B2 (ja) | Ｂｐｂベースのカーゴ運搬システム | |
| CN114828895A (zh) | 制备基于艾日布林的抗体-药物缀合物的方法 | |
| AU2021274149B2 (en) | Novel nucleolin-binding peptide and use thereof | |
| Jendryczko et al. | Peptibody based on FGFR1-binding peptides from the FGF4 sequence as a cancer-targeting agent | |
| Llanes et al. | Development of bombesin-tubulysin conjugates using multicomponent chemistry to functionalize both the payload and the homing peptide | |
| Rana et al. | Peptide Biomarkers and Assay Development | |
| US20130071395A1 (en) | Compositions and methods for treating pathologies | |
| KR20250089528A (ko) | 신규한 napi2b 항체를 함유하는 신규한 항체 약물 접합체, 치료 방법 및 이의 용도 | |
| Feng | One-Bead One-Compound Combinatorial Technology as Enabling Tool for Site-Specific Derivatization of Immunoglobulins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150121 Termination date: 20150923 |
|
| EXPY | Termination of patent right or utility model |